» Articles » PMID: 3706232

Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus

Overview
Journal Am J Dis Child
Specialty Pediatrics
Date 1986 Jun 1
PMID 3706232
Citations 642
Authors
Affiliations
Soon will be listed here.
Abstract

Respiratory syncytial virus is the most important cause of serious lower respiratory tract infection in children. For children followed up from birth in the Houston Family Study, the infection rate was 68.8/100 children less than 12 months of age and 82.6/100 during the second year of life. Virtually all children had been infected at least once by 24 months of age, and about one half had experienced two infections. Although lower respiratory tract disease (LRD) was common (22.4/100 during year 1 and 13.0/100 during year 2), most children had only one LRD illness. The risk of reinfection was inversely related to the level of neutralizing antibodies in the serum. Reinfection illnesses were generally mild, and risk of reinfection decreased to only 33.3/100 during year 4. Studies of children with LRD and surveys of hospitalizations provide the basis for an estimate of the number of children hospitalized each year during the respiratory syncytial virus epidemics. Almost 100,000 children in the United States experience an illness of sufficient severity to require hospitalization.

Citing Articles

Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada.

Bugden S, Mital S, Nguyen H BMC Med. 2025; 23(1):102.

PMID: 39984979 PMC: 11846277. DOI: 10.1186/s12916-025-03928-z.


A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus.

Lin M, Yin Y, Zhao X, Wang C, Zhu X, Zhan L Nat Commun. 2025; 16(1):1386.

PMID: 39910047 PMC: 11799228. DOI: 10.1038/s41467-025-56302-1.


Exploring the potential mediating role of systemic antibiotics in the association between early-life lower respiratory tract infections and asthma at age 5 in the CHILD study.

Medeleanu M, Reyna M, Dai D, Winsor G, Brinkman F, Verma R Front Allergy. 2025; 5:1463867.

PMID: 39906720 PMC: 11790586. DOI: 10.3389/falgy.2024.1463867.


Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus.

Shan X, Han R, Cheng X, Bing J, Qi Z, Sun S Vaccines (Basel). 2025; 13(1).

PMID: 39852872 PMC: 11769257. DOI: 10.3390/vaccines13010093.


[Interpretation of "Expert recommendations for the prevention of common respiratory viral infections in neonates": problems faced by respiratory syncytial virus infection in neonates].

Cheng C, Wang Y, Shi Y Zhongguo Dang Dai Er Ke Za Zhi. 2025; 27(1):26-32.

PMID: 39825648 PMC: 11750237. DOI: 10.7499/j.issn.1008-8830.2409033.